Navigation Links
Chronic Lung Disease - Axentis Pharma Attracts Investment Interest
Date:2/2/2009

ded to join Axentis.

The increasing interest in Axentis and its lead product also resulted in a presentation at the Biotech Showcase 2009 in San Francisco by the company's CEO Dr. Helmut Brunar. Amongst the well over 225 companies present at the event, he had the privilege of presenting the company's success. "Our financial position is sufficiently strong that we decided to wait with a major round of financing until early 2010. Now is therefore the right time to present ourselves in the best light to powerful investors. Our lead product ARB-CF0223 - also known as Fluidosome(R) tobramycin - is expected to generate a peak annual turnover of approx. 100 million EUR within five years of market launch. The investment that we will be seeking in early 2010 will see us through until this entry onto the market. I consider Axentis an extremely attractive investment option. The feedback I received in San Francisco certainly confirmed this personal judgment."

The next opportunity to meet representatives of Axentis Pharma at European conferences will be at the BioSquare in Lyon, France, on March 9 to 11.

About Axentis Pharma AG (http://www.axentispharma.com)

Axentis Pharma AG is a Swiss company located in Zurich with a focus on developing therapeutic solutions for respiratory diseases, most prominently cystic fibrosis. Axentis' lead product is in phase II clinical trials. Market registration / approval is expected in 2012.

About Fluidosome(R) technology

Axentis Pharma's Fluidosome(R) technology uses biocompatible lipids endogenous to the lung that are formulated into small liposomes. This nanocapsule platform offers wide-ranging potential to cater to unmet medical needs such as cystic fibrosis and other respiratory diseases. In the case of Fluidosome(R) tobramycin, the interaction between tobramycin and the microbial c
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
2. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
3. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
4. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
5. Pharos Innovations Joins Partnership to Fight Chronic Disease
6. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
7. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
8. New Company to Develop Nutritional Interventions Against Chronic Inflammatory and Infectious Diseases
9. Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During Live Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
10. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... The Center for Molecular,Medicine (CMM) today announced it is ... a new, FDA-approved test that will aid in the ... ) is offering the CellSearch(TM) System from,Veridex (http://www.veridex.com ... managing,patients with metastatic prostate cancer (MPC). The CMM made ...
... Mass., Feb. 28 A free white ... laboratory environmental health and,safety (EH&S) compliance programs ... ., "Small and midsized companies and ... and safety compliance programs,involving federal, state, and ...
... VPHM ) today announced it will present at ... Conference at 1:30,P.M. ET on Wednesday, March 5, 2008. ... New York City., ViroPharma,s presentation will be webcast ... a period of 14 days following,the conference., About ...
Cached Biology Technology:Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer 2White Paper Details Environmental Health & Safety Compliance Strategies for Laboratories 2
(Date:7/10/2014)... DALLAS , July 3, 2014 ... Sensors Market by Type (Swipe And Area), Material (Optical ... Defense, Healthcare, Commercial Security and Banking & Finance), and ... 2020", published by MarketsandMarkets, the global Fingerprint Sensors Market ... at a high CAGR of 16.8% from 2014 to ...
(Date:7/10/2014)... , July 7, 2014 ... Market Research "Electronic Access Control Systems Market Global Forecast, ... 2019," the global Electronic Access Control systems market was ... expected to grow at a CAGR of 12.6% from ... USD 31,187.8 million in 2019. Browse the ...
(Date:7/10/2014)... 2014 The widespread adoption of the ... by meaningful use and related federal programs, is ... laboratory information. Now, more than ever, pathologists need ... informatics in order to deliver high quality and ... educational needs of pathologists in this evolving health ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4
... causes those painful lip blisters known as cold sores has an ... it to literally blast its infectious DNA into human cells, scientists ... mechanism the first in a human virus opens the ... study in the Journal of the American Chemical Society . ...
... revealed new images which provide the clearest picture yet ... and tumours. , They show how the cells, which ... human body, change the organisation of their surface molecules, ... viral-infected or tumour cells., Professor Daniel Davis, who has ...
... HUNTSVILLE, Ala -- Even in the absence of a ... and intellectual challenges is helpful to physicians and families. ... high throughput genomic sequencing to meet major diagnostic needs ... totaling more than $7.6 million from the National Institutes ...
Cached Biology News:Researchers reveal the clearest new pictures of immune cells 2HudsonAlpha awarded grant to improve diagnoses of childhood genetic disorders 2
...
Histone H2A Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Detects ~14 kDa Histone H2A. It does not cross-react with other Histones. Reacts with human/mouse/rat. Performs w...
Contains L-glutamine...
... PhosphatidylEthanolamine-Binding Protein (PEBP) does not share ... inhibitors. PEBP is expressed in ... ovary, muscle, and stomach. One ... is exerting inhibitory activity against several ...
Biology Products: